Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?
British Journal of Clinical Pharmacology · 2023
DOI: 10.1111/bcp.15684 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Minna Lehtisalo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Organic Anion Transporters, Rhabdomyolysis, Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: H2020 European Research Council, Sigrid Juséliuksen Säätiö, Suomen Kulttuurirahasto.
Abstract (Originalsprache)
We present 3 patients diagnosed with rhabdomyolysis 1–6 months after the initiation of concomitant rosuvastatin and ticagrelor medication. A literature review and Food and Drug Administration adverse event reporting system revealed >40 reports of rhabdomyolysis during concomitant ticagrelor and rosuvastatin, including 3 with a fatal outcome. We show that ticagrelor inhibits breast cancer resistance protein‐, organic anion transporting polypeptide (OATP) 1B1‐, 1B3‐ and 2B1‐mediated transport of rosuvastatin in vitro with half‐maximal unbound inhibitory concentrations of 0.36, 4.13, 7.5 and 3.26 μM, respectively. A static drug interaction model predicted that ticagrelor may inhibit intestinal breast cancer resistance protein and thus increase rosuvastatin plasma exposure 2.1‐fold, whereas the OATP‐mediated hepatic uptake of rosuvastatin should not be inhibited due to relatively low portal ticagrelor concentrations. Taken together, concomitant use of ticagrelor with rosuvastatin may increase the systemic exposure to rosuvastatin and the risk of rosuvastatin‐induced rhabdomyolysis. Further studies are warranted to investigate the potential pharmacokinetic interaction between ticagrelor and rosuvastatin in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
- Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.
- Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
- Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
- Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.
- Genetics Laboratory, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Mikko Niemi
Förderung
- H2020 European Research Council
- Sigrid Juséliuksen Säätiö
- Suomen Kulttuurirahasto
Zitieren
APA
Lehtisalo, M., Kiander, W., Filppula, A. M., Deng, F., Kidron, H., Korhonen, M., Sinkko, J., Koivula, K., & Niemi, M. (2023). Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15684
Vancouver
Lehtisalo M, Kiander W, Filppula AM, Deng F, Kidron H, Korhonen M, et al. Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15684
BibTeX
@article{Lehtisalo2023,
author = {Lehtisalo, Minna and Kiander, Wilma and Filppula, Anne M and Deng, Feng and Kidron, Heidi and Korhonen, Mari and Sinkko, Johanna and Koivula, Kimmo and Niemi, Mikko},
title = {Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1111/bcp.15684}
}
EUVIMED